DCAL at iPHEX 2024 - India's Largest Global Pharmaceutical Exhibition
New Delhi, INDIA (August 28 - 30, 2024) - We were thrilled to showcase our formulation business portfolio at India's most prestigious global pharmaceutical exhibition, the iPHEX 2024. Our team exhibited our key strengths in soft gel formulations comprising superior products catering to emerging health and wellness needs. They also gave customers an extensive overview of our core capabilities in Contract Research Manufacturing (CRM), Contract Development and Manufacturing (CDM), Contract Research (CRO), etc.
We had the pleasure of meeting customers and visitors from all over the globe. It was a great opportunity for our team to communicate to a global audience about our unmatched capabilities in the formulation business. iPHEX 2024 was the perfect platform to showcase DCAL's entry into, and capabilities in, soft gel capsule formulation and represent our global mega-brand, Dishman Carbogen Amcis Ltd.
This exhibition brings the drugs, pharmaceutical and healthcare industries- all under one roof. It showcases Indian pharmaceutical products and technologies to a global audience. We met focused overseas buyers and new and existing customers looking for new opportunities in the soft gel capsules formulations market. Our team met 50+ overseas buyers and more than 100 Indian pharma professional visitors. Key customers from different regions expressed great interest in being associated with us.
-
Africa Continent - Nigeria, Kenya, Tanzania, Ghana, Sierra Leone, Burkina Faso, Rwanda, South Africa, St. Lucia, Guyana, etc.
-
South East Asia – Philippines, Cambodia, Myanmar, Malaysia, Vietnam, India
-
CIS: Uzbekistan, Turkey, Russia, Siberia, Uzbekistan
-
Latin & Central America – Guatemala, Peru, Ecuador, Mexico, Bolivia
-
Others – United Arab Emirates
Speaking about his experience at iPHEX 2024 and business prospects, Mr. Badarinarayan Herur, Head - Formulations, Dishman Carbogen Amcis Ltd said:
“Soft gelatin capsule formulations have a bright future. We have received multiple enquiries for CRAMS opportunities in soft gel capsule formulations. The CRAMS market demand is high due to the scarcity of skilled quality players in this formulation segment. The core strengths of DCAL are its science-based approach towards product development, regulatory-sufficiency documentation with an international standard manufacturing facility, and support staff with in-depth technical knowledge and experience in soft gel capsules technical know-how. Our core development strength is converting very poorly soluble API into soft gel formulation to enhance bioavailability.
As a new entrant in the soft gel capsule formulation business, we keep working towards the diversification of product portfolios in different therapeutic ranges with a scientific approach. With a wide diversified range of products, we want our customers to meet the market needs and demands. At iPHEX, we were proud to connect with overseas buyers and Indian visitors who are familiar with the Dishman brand in the API business. They were very impressed with our venture into the very niche formulation category of soft gelatin capsule dosage forms CRAMS business.”
- Hits: 2803